Archives — May 2015 back to current month (5)
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over.
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.
It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments. He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this interview with The Life Sciences Report, the founder and president of Canada-based StoneCastle Investment Management spotlights six names that have proven themselves with good runs but have potential for much bigger gains.
|"PMN has achieved a lot with very little, and its understanding of the mechanism of action of Alzheimer's is quite significant."|
|"DRRX's data indicate that NASH patients had 10-30% greater drug exposure as compared to MCS, and DUR-928 was well tolerated overall."|
|"RGS' strategy is to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."|